Hainsworth P J, Henderson M A, Stillwell R G, Bennett R C
University of Melbourne, Department of Surgery, Australia.
Eur J Surg Oncol. 1991 Feb;17(1):9-15.
In a prospective study of 75 breast carcinomas, monoclonal antibodies EGFR1, Anti-serum 21N (As21N) and RAP-5 were used to assess immunohistochemically expression of Epidermal Growth Factor Receptor (EGFR), c-erbB-2 oncoprotein and ras protein p21. A careful comparison was made of their relative prognostic significance. Positive staining was seen with EGFR1 in 12/71 cancers (17%) and with As21N in 16/75 cancers (21%). Positive staining with RAP-5 occurred in all cancers and benign breast tissue, but varied in intensity. EGFR expression correlated with the number of involved lymph nodes, histological grade, estrogen and progesterone receptor (ER, PR) levels and the Melbourne Prognostic Index. C-erbB-2 and ras expression both correlated with ER levels and EGFR, but not with the Prognostic Index. Based on an immunohistochemical technique, EGFR expression emerges as the parameter with strongest prognostic associations.
在一项对75例乳腺癌的前瞻性研究中，使用单克隆抗体EGFR1、抗血清21N（As21N）和RAP - 5通过免疫组织化学方法评估表皮生长因子受体（EGFR）、c - erbB - 2癌蛋白和ras蛋白p21的表达。对它们的相对预后意义进行了仔细比较。在71例癌症中有12例（17%）EGFR1染色呈阳性，75例癌症中有16例（21%）As21N染色呈阳性。RAP - 5在所有癌症和良性乳腺组织中均呈阳性染色，但强度有所不同。EGFR表达与受累淋巴结数量、组织学分级、雌激素和孕激素受体（ER、PR）水平以及墨尔本预后指数相关。C - erbB - 2和ras表达均与ER水平和EGFR相关，但与预后指数无关。基于免疫组织化学技术，EGFR表达成为具有最强预后关联的参数。
